ciclopirox 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antimycotics, pyridone derivatives | 636 | 29342-05-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of ciclopirox has been investigated using various in vitro and in vivo infection models. One in vitro study suggested that ciclopirox acts by chelation of polyvalent cations (Fe+3 or Al+3) resulting in the inhibition of the metal-dependent enzymes that are responsible for the degradation of peroxides within the fungal cell. The clinical significance of this observation is not known.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 1982 | FDA | MEDIMETRIKS PHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| PRIDE syndrome | 31.37 | 20.78 | 4 | 1833 | 16 | 63487169 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device dislocation | 147.05 | 28.62 | 35 | 1067 | 6214 | 34949615 |
| Device malfunction | 133.99 | 28.62 | 36 | 1066 | 10385 | 34945444 |
| Drug ineffective | 56.54 | 28.62 | 70 | 1032 | 456681 | 34499148 |
| Angioplasty | 30.81 | 28.62 | 7 | 1095 | 1003 | 34954826 |
| Nail injury | 28.79 | 28.62 | 4 | 1098 | 31 | 34955798 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Device malfunction | 146.28 | 23.19 | 44 | 2173 | 21404 | 79720767 |
| Device dislocation | 137.98 | 23.19 | 44 | 2173 | 25926 | 79716245 |
| Drug ineffective | 47.75 | 23.19 | 97 | 2120 | 1080816 | 78661355 |
| PRIDE syndrome | 31.33 | 23.19 | 4 | 2213 | 17 | 79742154 |
| Administration site dermatitis | 28.47 | 23.19 | 3 | 2214 | 0 | 79742171 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AE14 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Other antifungals for topical use |
| ATC | G01AX12 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Other antiinfectives and antiseptics |
| FDA MoA | N0000000150 | Protein Synthesis Inhibitors |
| FDA PE | N0000008577 | Decreased DNA Replication |
| FDA PE | N0000008841 | Decreased Protein Synthesis |
| FDA PE | N0000008853 | Decreased RNA Replication |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| CHEBI has role | CHEBI:33282 | bactericides |
| CHEBI has role | CHEBI:59010 | antiseborrheics |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Tinea pedis | indication | 6020002 | DOID:12403 |
| Candidiasis of skin | indication | 49883006 | |
| Seborrheic dermatitis | indication | 50563003 | DOID:8741 |
| Pityriasis versicolor | indication | 56454009 | DOID:9060 |
| Tinea corporis | indication | 84849002 | |
| Pityriasis simplex | indication | 200767005 | |
| Tinea cruris | indication | 399029005 | |
| Onychomycosis due to dermatophyte | indication | 402134005 | |
| Skin irritation | contraindication | 367466007 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.74 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Poly [ADP-ribose] polymerase 1 | Enzyme | INHIBITOR | IC50 | 6.80 | IUPHAR | ||||
| Deoxyhypusine hydroxylase | Enzyme | IC50 | 5.30 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019678 | VUID |
| N0000147770 | NUI |
| D01364 | KEGG_DRUG |
| 41621-49-2 | SECONDARY_CAS_RN |
| 21090 | RXNORM |
| 4018464 | VANDF |
| 4019678 | VANDF |
| C0055711 | UMLSCUI |
| CHEBI:453011 | CHEBI |
| CHEMBL1413 | ChEMBL_ID |
| DB01188 | DRUGBANK_ID |
| CHEMBL242580 | ChEMBL_ID |
| D000077768 | MESH_DESCRIPTOR_UI |
| 2749 | PUBCHEM_CID |
| 11349 | IUPHAR_LIGAND_ID |
| 3101 | INN_ID |
| 19W019ZDRJ | UNII |
| 16731 | MMSL |
| 207997 | MMSL |
| 44089 | MMSL |
| 4445 | MMSL |
| 8601 | MMSL |
| 002925 | NDDF |
| 004961 | NDDF |
| 372854000 | SNOMEDCT_US |
| 70169009 | SNOMEDCT_US |
| 79736009 | SNOMEDCT_US |
| B4O | PDB_CHEM_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0314 | LOTION | 7.70 mg | TOPICAL | ANDA | 16 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0407 | GEL | 7.70 mg | TOPICAL | ANDA | 19 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0449 | SHAMPOO | 10 mg | TOPICAL | ANDA | 25 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0522 | SHAMPOO | 10 mg | TOPICAL | NDA authorized generic | 27 sections |
| CICLOPIROX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0574-2061 | GEL | 7.70 mg | TOPICAL | ANDA | 20 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2159 | SHAMPOO | 10 mg | TOPICAL | ANDA | 16 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0317 | SOLUTION | 80 mg | TOPICAL | ANDA | 12 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0317 | SOLUTION | 80 mg | TOPICAL | ANDA | 12 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0638 | CREAM | 7.70 mg | TOPICAL | ANDA | 15 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0713-0638 | CREAM | 7.70 mg | TOPICAL | ANDA | 15 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-475 | SOLUTION | 71.30 mg | TOPICAL | ANDA | 24 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42192-715 | SOLUTION | 80 mg | TOPICAL | ANDA | 10 sections |
| Ciclodan | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43538-500 | SOLUTION | 2.28 g | TOPICAL | ANDA | 24 sections |
| Loprox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43538-540 | CREAM | 7.70 mg | TOPICAL | NDA | 20 sections |
| Loprox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43538-550 | SUSPENSION | 7.70 mg | TOPICAL | NDA | 20 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-138 | CREAM | 7.70 mg | TOPICAL | ANDA | 16 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-138 | CREAM | 7.70 mg | TOPICAL | ANDA | 16 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-141 | SOLUTION | 80 mg | TOPICAL | ANDA | 23 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-141 | SOLUTION | 80 mg | TOPICAL | ANDA | 23 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-400 | SUSPENSION | 7.70 mg | TOPICAL | ANDA | 17 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-400 | SUSPENSION | 7.70 mg | TOPICAL | ANDA | 17 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-401 | SHAMPOO | 1 g | TOPICAL | ANDA | 25 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-401 | SHAMPOO | 1 g | TOPICAL | ANDA | 25 sections |
| CICLOPIROX OLAMINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49999-646 | CREAM | 7.70 mg | TOPICAL | ANDA | 11 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-6562 | SOLUTION | 80 mg | TOPICAL | ANDA | 10 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-419 | SOLUTION | 71.30 mg | TOPICAL | ANDA | 24 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-419 | SOLUTION | 71.30 mg | TOPICAL | ANDA | 24 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-419 | SOLUTION | 71.30 mg | TOPICAL | ANDA | 24 sections |
| Ciclopirox Olamine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1318 | CREAM | 7.70 mg | TOPICAL | ANDA | 20 sections |
| Ciclopirox | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-1323 | SUSPENSION | 7.70 mg | TOPICAL | ANDA | 18 sections |